Author Index

Search or browse for an author across our entire electronic archive

Search results for: T
Results 131 - 140 of 1359 shown below

  • Takeda, H

    H Takeda, H Miyoshi, Y Tamai, M Oshima and M M Taketo

    Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas

    doi:10.1038/sj.bjc.6601584

  • Y Takehara, H Sakahara, H Masunaga, S Isogai, N Kodaira, H Takeda, T Saga, S Nakajima and I Sakata

    Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice

    doi:10.1054/bjoc.2001.1802

  • Takeda, K

    M Yamada, S Kudoh, H Fukuda, K Nakagawa, N Yamamoto, Y Nishimura, S Negoro, K Takeda, M Tanaka and M Fukuoka

    Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

    doi:10.1038/sj.bjc.6600464

  • I Sekine, H Nokihara, K Takeda, Y Nishiwaki, K Nakagawa, H Isobe, K Mori, K Matsui, N Saijo and T Tamura

    Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

    advance online publication, 2008-02-05 00:00:00.000;

    doi:10.1038/sj.bjc.6604233

  • H Kunitoh, T Tamura, T Shibata, K Nakagawa, K Takeda, Y Nishiwaki, Y Osaki, K Noda, A Yokoyama and N Saijo

    A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

    advance online publication, 2009-10-06 00:00:00.000;

    doi:10.1038/sj.bjc.6605347

  • K Takeda, S Negoro, S Kudoh, K Okishio, N Masuda, M Takada, M Tanaka, T Nakajima and T Tada

    Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer

    doi:10.1038/sj.bjc.6690233

  • L Ding, M Sunamura, T Kodama, J Yamauchi, D G Duda, H Shimamura, K Shibuya, K Takeda and S Matsuno

    In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells

    doi:10.1054/bjoc.2001.1911

  • Takeda, M

    M Kimura, Y Tomita, T Imai, T Saito, A Katagiri, T Tanikawa, M Takeda and K Takahashi

    Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

    doi:10.1038/sj.bjc.6690576

  • Takeda, S

    S Nomoto, T Kinoshita, K Kato, S Otani, H Kasuya, S Takeda, N Kanazumi, H Sugimoto and A Nakao

    Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma

    advance online publication, 2007-10-30 00:00:00.000;

    doi:10.1038/sj.bjc.6604016

  • S Nomoto, T Kinoshita, T Mori, K Kato, H Sugimoto, N Kanazumi, S Takeda and A Nakao

    Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer

    advance online publication, 2008-05-13 00:00:00.000;

    doi:10.1038/sj.bjc.6604333

  • Takeda, T

    Y Ito, N Matsuura, M Sakon, T Takeda, K Umeshita, H Nagano, S Nakamori, K Dono, M Tsujimoto, M Nakahara, K Nakao and M Monden

    Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma

    doi:10.1038/sj.bjc.6690758

  • Y Ito, M Monden, T Takeda, H Eguchi, K Umeshita, H Nagano, S Nakamori, K Dono, M Sakon, M Nakamura, M Tsujimoto, M Nakahara, K Nakao, Y Yokosaki and N Matsuura

    The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma

    doi:10.1054/bjoc.1999.1065

  • Y Ito, T Takeda, M Sakon, M Tsujimoto, S Higashiyama, K Noda, E Miyoshi, M Monden and N Matsuura

    Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma

    doi:10.1054/bjoc.2000.1580

  • Takeda, Y

    Y Takeda, E Tsuduki, S Izumi, M Hojo, M Kamimura, G Naka, K Kobayashi and K Kudo

    A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

    advance online publication, 2005-11-15 00:00:00.000;

    doi:10.1038/sj.bjc.6602866

  • T Noda, H Nagano, I Takemasa, S Yoshioka, M Murakami, H Wada, S Kobayashi, S Marubashi, Y Takeda, K Dono, K Umeshita, N Matsuura, K Matsubara, Y Doki, M Mori and M Monden

    Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma

    advance online publication, 2009-04-28 00:00:00.000;

    doi:10.1038/sj.bjc.6605064

  • Takedatsu, H

    K Azuma, S Shichijo, H Takedatsu, N Komatsu, H Sawamizu and K Itoh

    Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients

    doi:10.1038/sj.bjc.6601203

  • Takehara, Y

    Y Takehara, H Sakahara, H Masunaga, S Isogai, N Kodaira, H Takeda, T Saga, S Nakajima and I Sakata

    Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice

    doi:10.1054/bjoc.2001.1802

  • Takei, H

    J Horiguchi, H Takei, Y Koibuchi, K Iijima, J Ninomiya, K Uchida, R Ochiai, M Yoshida, T Yokoe, Y Iino and Y Morishita

    Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer

    doi:10.1038/sj.bjc.6600040

  • Takei, Y

    H Tanaka, N Fujita, R Sugimoto, N Urawa, S Horiike, Y Kobayashi, M Iwasa, N Ma, S Kawanishi, S Watanabe, M Kaito and Y Takei

    Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C

    advance online publication, 2008-01-29 00:00:00.000;

    doi:10.1038/sj.bjc.6604204